The UK’s National Institute for Health and Care (NICE) has approved Gedeon Richter’s Ryeqo ...

Endometriosis affects millions of people - and this new breakthrough treatment could be a game-changer for some ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clearside Biomedical (CLSD – Research Report) ...

Gedeon Richter acquired rights to the drug earlier that year in Europe, Russia and the Commonwealth of Independent States (CIS), Latin America, Australia, and New Zealand.

Nice initially rejected the drug, but new evidence was provided by the manufacturer Gedeon Richter to address questions about effectiveness and value for money. The drug will only be made available on ...

The new drug, called relugolix-estradiol-norethisterone, is a combination pill that blocks specific hormones that contribute to endometriosis, while also providing necessary hormone replacement ...

I Gedeon Richter Plc. announces today that the European Medicines Agency has accepted Richter’s marketing authorization application (MAA) for ...

Nice initially rejected the drug, but new evidence was provided by the manufacturer Gedeon Richter to address questions about effectiveness and value for money. The drug will only be made available on ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...